tiprankstipranks
OrganoClick AB (SE:ORGC)
:ORGC
Want to see SE:ORGC full AI Analyst Report?

OrganoClick AB (ORGC) AI Stock Analysis

0 Followers

Top Page

SE:ORGC

OrganoClick AB

(ORGC)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 5.2)
Rating:42Neutral
Price Target:
kr0.42
▼(-76.40% Downside)
Action:Reiterated
Date:06/22/26
The score is held down primarily by strained financial performance (declining revenue, deep losses, and very high leverage with a thin equity cushion). Technicals also weigh negatively as the stock trades below all key moving averages with a negative MACD. Valuation contributes only modestly because the negative P/E and missing dividend yield provide limited support.
Positive Factors
Improving cash generation
Operating cash flow turning positive after a prior negative year shows the core business is beginning to generate cash from operations. This improves near-term liquidity, supports working-capital needs, and reduces immediate refinancing pressure, aiding structural viability while free cash flow remains a work in progress.
Negative Factors
Declining and inconsistent revenue
A continuing revenue decline and multi-year inconsistency undermine scale economics and make it harder to achieve profitable operations. Weak top-line trends limit the ability to leverage fixed costs, complicate forecasting and commercial investments, and impair the path to sustainable profitability absent reliable revenue recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash generation
Operating cash flow turning positive after a prior negative year shows the core business is beginning to generate cash from operations. This improves near-term liquidity, supports working-capital needs, and reduces immediate refinancing pressure, aiding structural viability while free cash flow remains a work in progress.
Read all positive factors

OrganoClick AB (ORGC) vs. iShares MSCI Sweden ETF (EWD)

OrganoClick AB Business Overview & Revenue Model

Company Description
OrganoClick AB (publ), a technology firm based in Täby, Sweden, was established in 2006. The company specializes in the development, production, and sale of innovative fiber-based materials and chemicals for applications spanning wood treatment, t...
How the Company Makes Money
OrganoClick makes money primarily by selling its bio-based chemical products and materials-technology solutions to customers (B2B) and, to a lesser extent, through branded product sales (B2C/B2B depending on channel). Key revenue streams typically...

OrganoClick AB Financial Statement Overview

Summary
Weak fundamentals: TTM revenue fell 7.6% to 98.2m, margins are low (~14–15% gross), and the company remains deeply loss-making (TTM net margin ~-35%). Balance sheet risk is elevated with very high leverage (debt 77.4m vs equity 14.0m; ~5.5x debt-to-equity) and strongly negative ROE (~-1.54). A partial offset is operating cash flow turning positive (1.8m), but free cash flow is still negative (-3.8m).
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
28
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue98.16M106.19M127.23M145.87M115.05M110.06M
Gross Profit14.27M14.86M31.84M35.39M12.94M18.51M
EBITDA-11.12M-12.80M5.71M5.95M-21.19M-12.92M
Net Income-34.52M-36.37M-17.97M-15.77M-41.62M-31.03M
Balance Sheet
Total Assets147.69M135.22M126.98M150.75M162.86M188.39M
Cash, Cash Equivalents and Short-Term Investments3.05M2.68M538.00K10.74M15.20M34.25M
Total Debt77.43M77.78M51.67M62.39M61.68M53.54M
Total Liabilities128.92M114.81M89.15M97.34M95.30M80.66M
Stockholders Equity14.03M15.18M28.98M44.58M58.78M100.33M
Cash Flow
Free Cash Flow-3.82M-10.51M-5.51M-8.08M-35.35M-52.34M
Operating Cash Flow1.77M-8.29M3.60M533.00K-21.22M-37.69M
Investing Cash Flow-10.38M-10.99M-9.11M-8.61M-7.45M-14.65M
Financing Cash Flow11.13M21.42M-4.69M3.60M9.63M54.56M

OrganoClick AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.78
Price Trends
50DMA
0.61
Negative
100DMA
1.04
Negative
200DMA
1.38
Negative
Market Momentum
MACD
-0.06
Negative
RSI
40.20
Neutral
STOCH
42.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Negative. The current price of 1.78 is above the 20-day moving average (MA) of 0.46, above the 50-day MA of 0.61, and above the 200-day MA of 1.38, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 40.20 is Neutral, neither overbought nor oversold. The STOCH value of 42.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ORGC.

OrganoClick AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
55
Neutral
kr311.58M-14.27-9.48%-4.50%-62.45%
50
Neutral
kr188.48M-30.87-7.45%2.89%-16.65%48.43%
47
Neutral
kr53.38M-4.00
46
Neutral
kr386.16M-8.00-56.20%-50.16%
44
Neutral
kr49.11M-0.80-75.93%0.00%28.17%58.48%
42
Neutral
kr86.53M-1.25-153.91%-21.13%-66.28%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ORGC
OrganoClick AB
0.41
-1.47
-78.15%
SE:NEXAM
Nexam Chemical Holding AB
3.21
-0.66
-17.05%
SE:AERO
Svenska Aerogel Holding AB
0.99
-0.39
-28.55%
SE:POLYG
Polygiene AB
5.10
-7.00
-57.85%
SE:IMPC
Impact Coatings AB
3.78
0.59
18.68%
SE:XPC
XP Chemistries AB
0.18
-0.06
-26.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 22, 2026